Cel-Sci

FDA request extends CEL-SCI's multidecade Multikine journey

CEL-SCI will need another clinical trial for its Multikine cancer drug—which the company has long trumpeted as a promising therapy despite shaky data.

Annalee Armstrong Jul 14, 2023 10:32am

Cel-Sci CEO tries to spin cancer trial failure into an FDA win

Jul 7, 2021 3:40pm

Cel-Sci cancer phase 3 misses primary endpoint, sinking stock

Jun 29, 2021 8:45am

Embattled Cel-Sci to tackle COVID-19 with immunotherapy tech

Mar 24, 2020 7:55am

Cel-Sci CEO paints 'promising future' in letter to shareholders

Aug 22, 2018 8:09am

Cel-Sci wins 4.5-year-long arbitration case against CRO

Jul 10, 2018 4:18pm